stockportfolio.pro
RMD vs ZTS: Which Stock Is the Better Buy?
ResMed Inc. and Zoetis Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — RMD vs ZTS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| ResMed Inc. (RMD) | Zoetis Inc. (ZTS) | |
|---|---|---|
| Market cap | $30.4B | $31.4B |
| Revenue (latest FY) | $5.15B | $9.47B |
| Net income (latest FY) | $1.40B | $2.67B |
| Revenue growth (5y CAGR) | 11.7% | 7.2% |
| Net margin | 27.2% | 28.2% |
| Return on equity | 23.5% | 78.3% |
| P/E ratio | 20.2 | 12.3 |
| Dividend yield | 1.1% | 2.8% |
| Profitable years (of last 10) | 10 | 10 |
| Positive free cash flow | Yes | Yes |
See the full RMD vs ZTS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open RMD's full financials → Open ZTS's full financials →More comparisons
Frequently asked questions
Which is bigger, RMD or ZTS?
Zoetis Inc. is larger by market capitalization — $31.4B versus $30.4B.
Which grows faster, RMD or ZTS?
Over the last five fiscal years, ResMed Inc. grew revenue faster — 11.7%/yr versus 7.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.